Moleculera BiosciencesPipeline
Power of precision medicine
We believe in the power of precision medicine and that when the root cause of chronic, debilitating disorders is identified and treated, patients can live longer, healthier lives. At Moleculera Biosciences, our team is committed to developing and commercializing groundbreaking autoantibody tests that identify an underlying autoimmune etiology in patients with difficult-to-treat CNS and cardiovascular disorders and direct treatment to improve patient outcomes.
Bringing hope and healing to patients with difficult-to-treat disorders
Moleculera Biosciences is advancing a robust pipeline of several autoantibody tests that aim to assist with diagnosis and treatment of immune-mediated cardiovascular, Long-COVID and neuro-degenerative disorders.
The company’s signature test, the Autoimmune Brain Panel™, has been utilized by more than 2,500 clinicians worldwide to help identify an underlying infection-triggered autoimmune process in patients with psychiatric and/or neurologic symptoms and assist with directing treatment.
Moleculera expects to commercialize additional panels including the Autoimmune Cardiovascular Panel™ for cardiovascular diseases, such as heart failure, cardiomyopathy, atrial fibrillation, and myocarditis, the Long-COVID Panel™ that combines the heart and brain antibody biomarkers for diagnosing and treatment-monitoring of patients with long-term symptoms following infection with SARS‑CoV‑2 and the Neuro-degenerative Disorder Panel™ for patients with dementia, Alzheimer’s disease and Parkinson’s disease.
